THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc.® (NasdaqCM:RPRX) today reported it has received Institutional Review Board (IRB) approval to commence the Phase IIb study of Androxal® in men with secondary hypogonadism. The Company has submitted the protocol for FDA comment and plans to begin enrolling subjects in January. Depending on the rate of subject enrollment, Repros hopes to have the study completed before the end of 2011.
